Upgrades:
Wells Fargo & Company (NYSE:WFC) was upgraded by equities researchers at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued on Monday, The Fly reports.
A number of other research analysts have also recently
issued reports on the company. BMO Capital Markets reduced their price
objective on Wells Fargo & Company from $35.00 to $31.00 and set a “market
perform” rating on the stock in a research note on Friday, October 16th. DA
Davidson raised Wells Fargo & Company from a “neutral” rating to a “buy”
rating and lifted their price target for the stock from $27.00 to $31.00 in a
research note on Thursday, November 19th. ValuEngine raised Wells Fargo &
Company from a “hold” rating to a “buy” rating in a research note on Wednesday,
November 25th. Odeon Capital Group upgraded shares of Wells Fargo & Company
from a “hold” rating to a “buy” rating in a report on Wednesday, September 2nd.
Finally, UBS Group upgraded shares of Wells Fargo & Company from a “sell”
rating to a “neutral” rating and upped their price target for the company from
$21.00 to $24.00 in a report on Friday, September 11th. One equities research
analyst has rated the stock with a sell rating, fourteen have issued a hold
rating and eleven have given a buy rating to the stock. The stock currently has
a consensus rating of “Hold” and a consensus target price of $31.30. Read
more …
AstraZeneca (NYSE:AZN) was upgraded by equities researchers at UBS Group from a "sell" rating to a "neutral" rating in a note issued to investors on Monday, The Fly reports.
Other equities research analysts also recently issued
research reports about the company. HSBC raised AstraZeneca from a
"reduce" rating to a "hold" rating in a research report on
Wednesday, November 11th. Berenberg Bank initiated coverage on AstraZeneca in a
research report on Tuesday, September 29th. They set a "buy" rating
on the stock. Oddo Bhf raised AstraZeneca from a "reduce" rating to a
"buy" rating in a research report on Wednesday, September 23rd.
Finally, Morgan Stanley reaffirmed an "equal weight" rating on shares
of AstraZeneca in a research report on Monday, November 23rd. One research
analyst has rated the stock with a sell rating, five have issued a hold rating
and seven have assigned a buy rating to the company's stock. The company currently
has a consensus rating of "Hold" and a consensus target price of
$61.00.
AZN opened at $52.61 on Monday. AstraZeneca has a 12-month
low of $36.15 and a 12-month high of $64.94. The company has a current ratio of
0.82, a quick ratio of 0.63 and a debt-to-equity ratio of 1.14. The business's
fifty day simple moving average is $53.81 and its 200-day simple moving average
is $54.53. The company has a market capitalization of $138.08 billion, a
price-to-earnings ratio of 63.39, a PEG ratio of 1.63 and a beta of 0.50. Read
more …
The Bank of New York Mellon (NYSE:BK) was upgraded by investment analysts at Morgan Stanley from an "underweight" rating to an "equal weight" rating in a note issued to investors on Monday, The Fly reports.
Several other equities analysts have also recently commented
on the stock. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon
Russell cut shares of The Bank of New York Mellon from a "buy" rating
to a "neutral" rating in a report on Tuesday, November 10th. Deutsche
Bank Aktiengesellschaft upgraded shares of The Bank of New York Mellon from a
"hold" rating to a "buy" rating and boosted their price
target for the company from $39.00 to $46.00 in a report on Wednesday, November
11th. Smith Barney Citigroup cut shares of The Bank of New York Mellon from a
"buy" rating to a "neutral" rating in a report on Tuesday,
November 10th. Bank of America cut shares of The Bank of New York Mellon from a
"neutral" rating to an "underperform" rating and lowered
their price target for the company from $42.00 to $39.00 in a report on Friday,
November 20th. Finally, Keefe, Bruyette & Woods cut shares of The Bank of
New York Mellon from an "outperform" rating to a "market
perform" rating and lowered their price target for the company from $47.00
to $43.00 in a report on Wednesday, November 18th. Three equities research
analysts have rated the stock with a sell rating, ten have assigned a hold
rating and nine have assigned a buy rating to the company's stock. The Bank of
New York Mellon has a consensus rating of "Hold" and an average
target price of $44.56. Read
more …
U.S. Bancorp (NYSE:USB) was upgraded by investment analysts at Morgan Stanley from an “underweight” rating to an “equal weight” rating in a research note issued on Monday, The Fly reports.
USB has been the subject of a number of other research
reports. Bank of America raised shares of U.S. Bancorp from an “underperform”
rating to a “neutral” rating and lifted their price objective for the company
from $39.00 to $41.00 in a research report on Wednesday, October 7th. JPMorgan
Chase & Co. raised their price target on shares of U.S. Bancorp from $37.50
to $43.50 and gave the stock an “underweight” rating in a research report on
Tuesday, October 6th. ValuEngine raised shares of U.S. Bancorp from a “sell”
rating to a “hold” rating in a report on Monday, November 2nd. Finally,
TheStreet raised shares of U.S. Bancorp from a “c” rating to a “b-” rating in a
report on Thursday, October 15th. Two research analysts have rated the stock
with a sell rating, ten have given a hold rating and eleven have given a buy
rating to the company. U.S. Bancorp presently has a consensus rating of “Hold”
and a consensus target price of $44.58. Read
more …